



Differentiating
Persistently Positive
COVID-19 Cases from
SARS-CoV-2
Reinfections Utilizing

Laboratory Evidence,

Virginia, 2020 – 2021



well-being of all people in Virginia.

Presented by: Jenny Crain<sup>1</sup>, MS, MPH and Haley Greene<sup>1</sup>, MPH

In collaboration with: Katherine McCombs<sup>1</sup>, MPH; Shelby Bennett<sup>2</sup>, MS


<sup>1</sup>VDH Division of Surveillance & Investigation, Office of Epidemiology; <sup>2</sup>Virginia Department of General Services, Division of Consolidated Laboratory Services

## **Objectives**

- After the session, the attendee will be able to highlight the value of conducting a real-time epidemiologic research study during an ongoing pandemic supported by genomic laboratory evidence.
- Participants will be able to understand the importance of whole genome sequencing (WGS) as a method for differentiating persistently positive COVID-19 cases from SARS-CoV-2 reinfection.
- Attendees will be able to compare the advantages and disadvantages of using genomic sequencing paired with case-level epidemiologic interview data to monitor genetic changes in the virus, over time, through enhanced surveillance of SARS-CoV-2 variants.




# Background



#### 2020 Research Questions - Re-interviews

- How do persistently positive COVID-19 cases' initial infection differ from subsequent SARS-CoV-2 reinfections, considering indicators of disease severity (symptoms, pneumonia, hospitalization, death)?
- II. Is reinfection risk greater in congregate settings or for patients with repeat exposures to confirmed cases?
- What can be learned by comparing reinfection cases to others with the same exposures in a healthcare facility outbreak?
  - \*Re-interviews: to improve exposure and disease severity data quality

## Methods




#### **Expanded 2020 Study - Case Definitions**


- 2020 COVID-19 cases with 2 +MATs >90 days apart (N=800) using these revised criteria
- Likely Persistent Positive (PP) cases: those with 1 or more intervening +MAT during the 90 day interval, but the specimen collection date must be >14 days after 1st +MAT (and without a neg MAT w/in 2 days of +)
- Likely Reinfections (Reinfx): those with 2 or more intervening neg MATs (at least 1 with specimen collection date 14-21 days after initial +)
- Cases with insufficient evidence or data to classify as either Persistent Positive cases or Reinfections



#### Study Selection Criteria for Likely Persistent Positive COVID-19 Cases and SARS-CoV-2 Reinfections, 2020 Analysis



## Days Between Confirmatory Test Results for 2020 COVID-19 Cases, with Two or More Positive MAT Specimens Collected >90 days Apart



#### 2021 Revised CSTE Case Definition

Person previously enumerated as a "Confirmed" (non-genomic sequencing) or "Probable" case

Person previously enumerated as a "Confirmed" case based on genomic sequencing

Yes

'detected' or SARS-CoV-2 specific Ag 'detected' by CLIA-certified provider or laboratory

AND specimen collection date >90 days later?

Yes

**Re-infection Case** 

Yes

SARS-CoV-2
sequencing results
from a new
positive specimen
demonstrates a
different lineage?

Yes

**Re-infection Case** 



## Results




#### 2020 — 2021 Results

- 2021: Total possible SARS-CoV-2 reinfections (2 MAT+s >90 days apart, includes 2021 only Sp. Coll. Dt.)
  - N=1,466 w/ Case Count=1 (Confirmed only)
  - n=265 Likely Persistent Positive COVID-19 cases
  - n=75 Likely Reinfections
- '20-'21: Total possible SARS-CoV-2 reinfections (2 MAT+s >90 days apart, includes '20-'21 Sp. Coll. Dt.)
  - N=10,057 w/ Case Count=1 (Confirmed only)
  - n=1,780 Likely Persistent Positive COVID-19 cases
  - n=389 Likely Reinfections




## Study Selection Criteria for Likely Persistent Positive COVID-19 Cases and SARS-CoV-2 Reinfections '20-'21 Analysis




# Early 2020: 'DOUG' mutation & Variants of Unknown Significance

Magnitude of Infection



Global Transition from D614 to G614 variants 36,410 Global Spike Sequences, 06/23/2020




https://lmg-labmanager.s3.amazonaws.com/assets/articleNo/23187/ilmg/42980/july3-2020-lanl-2-covid-19-strain-graph.jpg https://www.sheffield.ac.uk/news/polopoly\_fs/1.892282!/image/covidvirus.jpg






#### SARS-CoV-2 Variant Lineages by Specimen Collection Date





## Discussion

**Case Studies** 






#### **Reinfection Case Studies Timeline**

Timeline of events for each patient (PCR+ sp. coll. date used as proxy if onset date is unknown)




#### True Persistent Positive Case





#### **True Reinfection**

ID .	Sequence name QC Clade	Pango Ineage (Nextclade)	Mut.	non - ACGTN .	Ns :	Gaps .	Ins.	FS .	sc :		Nucleotide sequence ♥
0	@hCeV-19/USA/VA-CAV_VAS3N_00005585_01/2(N@@@@3 21J (Delta)	AV.39	41	0	373	47	0	0	0	91	
1	© hCd/-19/USA/VA-CAV_VAS3N_00005675_01/2400000000000000000000000000000000000	AY.103	46	0	833	13	0	0	0		





### Acknowledgements

